Navigation Links
OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO

VANCOUVER and CARLSBAD, CA, May 31, 2007 /PRNewswire-FirstCall/ - OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. today announced that preliminary data from ongoing clinical studies of OGX-011 will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO). Presentations will include data from a Phase II clinical study of OGX-011 in hormone refractory prostate cancer and data from a Phase I/II clinical study of OGX-011 in non-small cell lung cancer. ASCO takes place June 1-5, 2007 at McCormick Place in Chicago, Illinois.

    Information related to the presentations:


    Saturday, June 2, 2007


    Poster Presentation:   "A randomized Phase II study of OGX-011 in

                           combination with docetaxel and prednisone or

                           docetaxel and prednisone alone in patients with

                           metastatic hormone refractory prostate cancer

                           (HRPC)"

    Abstract Number:       5069

    Session:               Genitourinary (Prostate) Cancer, Poster Board

                           # 17

    Location:              E451a

    Session Time:          2:00 p.m. - 6:00 p.m.

    Presenter:             Kim N. Chi, M.D., FRCPC


    Poster Discussion:     "A randomized Phase II study of OGX-011 in

                           combination with docetaxel and prednisone or

                           docetaxel and prednisone alone in patients with

                           metastatic hormone refractory prostate cancer

                           (HRPC)"

    Abstract Number:       5069

    Session:               Genitourinary (Prostate) Cancer, Poster Board

                           # 17

    Location:              E Arie Crown Theater

    Session Date:          Saturday, June 2, 2007

    Session Time:          5:00 p.m. - 6:00 p.m.

    Presenter/Discussant:  Kim N. Chi, M.D./Celestia Higano, M.D.


    Sunday, June 3, 2007


    Poster Presentation:   "A
'"/>




Page: 1 2 3 4

Related medicine technology :

1. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OncoGenex and Isis Announce OGX Data Presented ASCO
(Date:9/18/2014)... DALLAS , September 18, 2014 ... "Temperature Management Market by Product (Surface & Intravascular Systems- Warming ... Suite), End User (Surgeon & Anesthesiologist, Nursing & ... 2019" published by MarketsandMarkets, this report studies the global ... 2014 to 2019. The market is expected to ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... Sept. 18, 2014  KIYATEC announced today that ... Business Innovation Research (SBIR) Phase II Contract from ... 27 institutes and centers that comprise the National ... the two year award, KIYATEC will expand its ... at the forefront of cancer therapy strategies: 1) ...
Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3
... Mich., Nov. 15, 2010 Adeona Pharmaceuticals, Inc. ... for serious central nervous system diseases, announced today its third ... operational achievements. Adeona,s Recent Clinical and Operational ... Alzheimer,s Disease All 60 patients ...
... to demo a new tool for personalized preventive medicine ... applying for FDA clearance, this comprehensive risk assessment tool, ... the thickness of the C-IMT and detects plaque in ... for screening and unlike anything else out there. ...
Cached Medicine Technology:Adeona Announces Third Quarter 2010 Financial Results and Achievements 2Adeona Announces Third Quarter 2010 Financial Results and Achievements 3Adeona Announces Third Quarter 2010 Financial Results and Achievements 4Adeona Announces Third Quarter 2010 Financial Results and Achievements 5Panasonic Unveils CardioHealth® Station - First Comprehensive Screening Solution to Detect Heart Disease in Asymptomatic Population 2
(Date:9/18/2014)... NJ (PRWEB) September 18, 2014 ... firm, announced today that President and co-founder John ... Journal’s Innovation Award Winners for 2014, recognizing the ... him as an emerging executive of the year. ... care and life sciences that continue to shape ...
(Date:9/18/2014)... Qualis Health, one of the nation’s leading ... paper, “Advancing Primary Care through the Patient-Centered Medical Home ... Authors Jeff Hummel, MD, MPH and Peggy C. Evans, ... in the work of becoming a Patient-Centered Medical Home ... objectives, such as generating and providing useful data that ...
(Date:9/18/2014)... Baltimore, MD (PRWEB) September 18, 2014 ... Award-winning celebrity and wellness advocate, and Frank Davis, ... Activz Whole-food Nutrition, are pleased to announce ... 150+ ways to make delicious, nutrition-packed meals using ... book is the next step in the ...
(Date:9/18/2014)... of international scientists have developed a new method to ... . , The Wildlife Conservation Society (WCS)-led research, published ... , describes the use of fecal samples from wild ... exposed to the virus. This represents a new tool ... change the way Ebola virus is studied and improve ...
(Date:9/18/2014)... expect to pay higher employee contributions for their health ... officers about the impact of the Patient Protection and ... conducted by the Darla Moore School of Business at ... Patrick Wright, a professor in strategic human resource management, ... Officers. The survey is distributed to more than 560 ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3
... regional networks , , FRIDAY, April 24 (HealthDay News) ... laboratory personnel has led to steady improvements in the ... a severe heart attack, new research shows. , The ... ST elevation myocardial infarction (STEMI), the deadliest type of ...
... Though soldiers tend to be healthier, trauma erases the advantage, ... Those serving in the armed forces tend to be in ... experienced combat duty, that initial health advantage is erased. , ... life than do non-combat veterans, according to a study that ...
... N.C. (April 23, 2009) Talecris Biotherapeutics, Inc. ... of life results from the largest clinical trial ... polyneuropathy (CIDP) in the April 14, 2009 issue ... that long-term treatment with Gamunex (Immune Globulin Intravenous ...
... ANGELES , April 24 MMR Information ... its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (collectively, "MMR") ... www.mymedicalrecords.com ) and electronic safe deposit box ... a Webinar on the company,s products for healthcare ...
... ABC,s hit television show Grey,s Anatomy has selected the ... its favorite charities and has listed the AAN Foundation on the Grey,s ... and Dr. Derek "McDreamy" Shepherd. Fans and the public are encouraged ... lieu of gifts. The public can buy a virtual brain for ...
... "Pregnant women need our assistance now so that abortion ... April 24 Cardinal Rigali, chair of the Committee ... Bishops (USCCB), wrote to all U.S. Representatives urging them ... 2035) re-introduced in the House by Rep. Lincoln Davis ...
Cached Medicine News:Health News:Coordination Has Led to Quicker Heart Treatment 2Health News:Combat Duty Harms Long-Term Health of Vets 2Health News:Combat Duty Harms Long-Term Health of Vets 3Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 2Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 3Health News:MMR Announces Webinar to Demonstrate MyMedicalRecords PHR Product Line 2Health News:MMR Announces Webinar to Demonstrate MyMedicalRecords PHR Product Line 3Health News:AAN Foundation Benefits from Grey's Anatomy 'Wedding Registry' 2Health News:Cardinal Rigali Praises House Re-Introduction of 'Pregnant Women Support Act,' Urges Co-Sponsorship 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: